URINARY TRACT INFECTIONS (UTI’S).
Many years of contract partnering in different areas of research has enabled Mologic to develop a quick and easy dipstick test. Although there are many alternative urine dipstick tests available, e.g. for nitrite, leukocyte esterase, protein and blood (Schmiemann, 2010), we believe that our new test, which measures levels of specific inflammatory biomarkers, will offer significant advantages in terms of sensitivity and specificity.
Urinary tract infections (UTI’s) are extremely common. They are usually caused by Escherichia coli, but other Enterobacteriaceae are also important causes of infection. The infection usually passes within a few days and is easily treated with a course of antibiotics.
UTI’s are more common in women, affecting them at least once in their lives. In the UK 2,000 healthy men develop a UTI each year. UTI’s are much less common in children.
Most UTIs are caused by bacteria that live in the digestive system. If these bacteria get into the urethra they can cause infection.
Symptoms include pain or a burning sensation when urinating (dysuria), the need to urinate often and pain in the lower abdomen in uncomplicated urethritis or cystitis.
Complications of a UTI are not common, but they can be serious. Complications usually only affect people with a pre-existing health condition, such as diabetes or a weakened immune system. They can include prostatitis, kidney infection, kidney failure and blood poisoning (sepsis).
OUR UTI ASSAY.
Our first new test will be a simple 5 minute assay for professional use in general practice surgeries to diagnose UTIs.
OUR RESEARCH PARTNERS.
Our expertise in Urinary Tract Infections is growing fast. Mologic works with leading clinical researchers and applied microbiologists to give our world class team the edge. For example, we are collaborating in an NHS NIHR “Invention for Innovation” (i4i) translational research project with experts at Cardiff University http://medicine.cf.ac.uk/news/i4i-grants/
Our urinary tract infection research has been attracting interest from clinical and industrial partners.